

PRESS RELEASE

ADVA BIOTECHNOLOGY AND GENCART COLLABORATE TO ADVANCE CAR-T THERAPY AVAILABILITY

Pittsburgh, April 2, 2025, GenCART and ADVA Biotechnology are pleased to announce a groundbreaking collaboration with GenCART to expand the availability of CAR-T therapies to patients. This partnership aims to bring cutting-edge cell therapy solutions directly to patients, enhancing treatment accessibility and efficiency.

At the core of this collaboration is a combination of the **ADVA X³** Platform and GenCART's unique CAR-T therapy.

The **ADVA X³** is a revolutionary solution that enables both centralized and point-of-care manufacturing, allowing CAR-T therapies to be produced near the patient or directly within hospital settings.

By decentralizing production, the **ADVA X³** platform significantly reduces costs and simplifies the manufacturing process, making advanced treatments more accessible and scalable.

Moreover, GenCART's unique CAR-T technology further enhances treatment efficacy, offering improved outcomes while also minimizing side effects commonly associated with traditional therapies. This combination of innovation in manufacturing and therapy development holds the promise of transforming patient care and providing faster, safer, and more effective treatments for those in need.

Dr. Ohad Karnieli, Adva Biotechnology's Founder and CEO: *"This partnership reflects both companies' commitment to improving patient outcomes and accelerating the adoption of next-generation cell therapies in the fight against cancer"*.

"The current cost of CAR-T therapy is unsustainable and represents a major barrier to patient access. Our partnership will reduce therapy costs and make this life-saving treatment accessible to patients worldwide. This marks an exciting opportunity to bridge gaps in healthcare and bring hope to those who previously lacked access", says **Dr. Mounzer Agha**, Founder and CEO and **Dr. Stanley Marks**, Founder and Chairman of GenCART.

About ADVA Biotechnology:

ADVA Biotechnology is a leading innovator in cell therapy manufacturing solutions, specializing in scalable, flexible platforms that streamline production while ensuring the highest quality and efficacy.

For more information, visit www.advabio.com.

About GenCART:

GenCART is a pioneer in CAR-T therapy development, offering cutting-edge solutions that improve the efficacy of treatment while reducing side effects and revolutionizing cancer care.

